Orchestra BioMed (OBIO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
25 Jun, 2026Opening remarks and agenda
Meeting called to order by the CEO and Chairperson, with introductions of key officers and the independent auditor present.
Inspector of Election and meeting secretary appointed; agenda and rules of conduct reviewed for orderly proceedings.
Five items of business outlined: director elections, auditor ratification, employee stock plan, executive compensation, and vote frequency.
Board and executive committee updates
Three current directors nominated for re-election to serve three-year terms until the 2029 annual meeting.
Shareholder proposals
No stockholder nominations for directors received; nominations closed.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Orchestra BioMed
- Net loss rose to $44.4M as pivotal trials advanced and cash runway extended into Q4 2027.OBIO
Q2 2026 - Strategic financing fuels pivotal AVIM trial and advances Virtue's sirolimus drug delivery innovation.OBIO
Piper Sandler 37th Annual Healthcare Conference - Pivotal cardiovascular device trials progress with strong partners and funding, targeting 2028 launches.OBIO
Sidoti Small-Cap Virtual Investor Conference - 2026 Employee Stock Purchase Plan approved, enabling employees to acquire up to 750,000 shares.OBIO
Proxy filing - Upcoming BackBeat and Virtue trial milestones signal strong growth and partnership-driven value.OBIO
Jefferies Global Healthcare Conference 2026 - Pivotal cardiovascular therapies advance toward commercialization with strong partner support.OBIO
Corporate presentation - Net loss widened to $20.7M as R&D spending rose, with cash runway into Q4 2027 and new FDA designation.OBIO
Q1 2026 - Board recommends approval of all annual meeting proposals, including compensation and governance.OBIO
Proxy filing - Key votes include director elections, auditor ratification, and executive pay approval.OBIO
Proxy filing